Compared with the GGT/ALT-low group, the patients in the GGT/ALT-high group had markedly poorer 1-, 3-, and 5-year OS rates (90.5%, 77.5%, and 69.9% vs. 97.5%, 90.6%, and 87.7%, respectively; P = 0.002) (Figure 1C) and DFS rates (74.3%, 56.5%, and 44.5% vs. 87.0%, 72.1%, and 65.4%, respectively; P = 0.003) (Figure 1D), suggesting a positive correlation between high GGT/ALT levels and poor survival in patients with HCC. This evidence concerns the gene GPT and hepatocellular carcinoma.